Western diamondback rattlesnake venom toxins (CAV)

Western diamondback rattlesnake (Crotalus atrox) venom toxins are a complex cocktail of bioactive proteins and peptides that serve as the primary mechanism for prey capture and digestion. The venom is dominated by snake venom metalloproteinases (SVMPs), which degrade vascular structures and cause significant local tissue necrosis and systemic hemorrhage. Other major toxin families include snake venom serine proteinases (SVSPs), which interfere with the host coagulation cascade leading to fibrinogen consumption, and phospholipases A2 (PLA2s), which exhibit myotoxic and pro-inflammatory activities. In clinical medicine, these toxins are the direct targets of polyvalent antivenoms such as CroFab and ANAVIP, which employ purified antibody fragments to neutralize the toxins' enzymatic and toxic motifs. Beyond their role in envenomation, specific venom components like disintegrins have provided structural templates for the development of modern anti-platelet medications. Managing toxicity involves monitoring hematological biomarkers like fibrinogen levels and platelet counts to assess the severity of coagulopathy and the efficacy of antivenom administration.

Other names

Crotalus atrox venomWestern diamondback rattlesnake toxinsWestern diamondback venomC. atrox venomRattlesnake venom

The primary therapeutic mechanism involves the use of antivenom, which contains antibody fragments (Fab or F(ab')2) that bind to and neutralize the toxins' active sites, facilitating their clearance and preventing further tissue damage. Experimental small molecules like varespladib target specific enzymatic components, such as phospholipase A2, to inhibit their catalytic activity and reduce systemic toxicity.